Molecular basis of agonism and antagonism in the oestrogen receptor
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Oestrogens are involved in the growth, development and homeostasis of a number of tissues. The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER). Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of molecular events culminating in the activation or repression of target genes. Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery. Here we report the crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxifene, at resolutions of 3.1 and 2.6 A, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties. Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes. In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously found that the full-length ERα dimer forms a symmetric tail-to-tail dimer in the ERα/SRC-3/p300 complex (Yi et al., 2015), consistent with the nature of palindromic DNA binding sequence, symmetric X-ray crystal structures of the ERα LBD (Brzozowski et al., 1997) and DBD dimers (Schwabe et al., 1993).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
In the citing paper
“the AR LBD interacts weakly with LXXLL motif-containing coactivators, such as SRCs, (Brzozowski et al., 1997; Dubbink et al., 2006; He et al., 2004; He et al., 1999; Matias et al., 2000; Nadal et al., 2017).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · cited 1×
“Data were integrated and reduced using the programs DENZO and SCALEPAC”
MethodPROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932 · cited 1×
“The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER”
BackgroundThe estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220 · cited 1×
“The ER LBDs are arranged as non-crystallographic dimers within both the E 2 and RAL complex crystals in a manner consistent with both the oligomeric state of liganded ER in solutio”
BackgroundCrystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/375377a0 · Cited by 1,177 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundCrystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid
Renaud, J.-P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/378681a0 · Cited by 1,097 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundA canonical structure for the ligand-binding domain of nuclear receptors
Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D., & Gronemeyer, H. (1996) · Nature Structural Biology · doi:10.1038/nsb0196-87 · Cited by 985 · cited 1×
“, and emphasizes the universal nature of this fold within this receptor superfamil”
Background
Cited by
Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β
Kuiper, G. G. J. M., Lemmen, J. G., Carlsson, B., Corton, J. C., Safe, S. H., van der Saag, P. T., van der Burg, B., & Gustafsson, J.-Å. (1998) · Endocrinology · doi:10.1210/endo.139.10.6216 · Cited by 4,203
Self-citationThe Protective Effects of Estrogen on the Cardiovascular System
Mendelsohn, M. E., & Karas, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402306 · Cited by 3,103
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
“RAL (Brzozowski et al., 1997; Tanenbaum et al., 1998).”
Self-citationA transmembrane intracellular estrogen receptor mediates rapid cell signaling
Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., & Prossnitz, E. R. (2005) · Science · doi:10.1126/science.1106943 · Cited by 2,302
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
“Intriguingly, the structures of the ER LBD bound to the antagonists raloxifene or dihydroxytamoxifen (OHT) demonstrate a distortion in the position of the AF2 helix (Brzozowski et al. 1997; Shiau et al. 1998) (Fig.”
BackgroundEstrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045
Physiological and Molecular Basis of Thyroid Hormone Action
Yen, P. M. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1097 · Cited by 2,011
Nilsson, S., Mäkelä, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., Enmark, E., Pettersson, K., Warner, M., & Gustafsson, J.-Å. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.4.1535 · Cited by 1,996
Self-citationLigand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., & Milburn, M. V. (1998) · Nature · doi:10.1038/25931 · Cited by 1,958
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857
Self-citationTargeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
“An example of how the therapeutic utility of drugs that function through interaction with a receptor is influenced by their MMOA is provided by the tissue-selective functional effects of the selective oestrogen receptor modulators (SERMs), which are mediated by SERM-induced structural changes in the oestrogen recepto”
BackgroundTherapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767
Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription
Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., & Brown, M. (2000) · Cell · doi:10.1016/s0092-8674(00)00188-4 · Cited by 1,657
“…(TAM) competes with E2 for ERa binding and induces a conformational change in which the recruit-with other data showing that the activity of RNA polymerase II is regulated by multisite phosphorylation on ment of p160 coactivators is blocked (Halachmi et al., 1994; Brzozowski et al., 1997).”
BackgroundNuclear Hormone Receptors and Gene Expression
Aranda, A., & Pascual, A. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1269 · Cited by 1,570
Métivier, R., Penot, G., Hübner, M. R., Reid, G., Brand, H., Koš, M., & Gannon, F. (2003) · Cell · doi:10.1016/s0092-8674(03)00934-6 · Cited by 1,431
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Self-citationMolecular recognition of fatty acids by peroxisome proliferator-activated receptors
Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., Brown, P. J., Sternbach, D. D., Lehmann, J. M., Wisely, G. B., Willson, T. M., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80467-0 · Cited by 1,169
Newell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,165
Dietary Isoflavones: Biological Effects and Relevance to Human Health
Setchell, K. D. R., & Cassidy, A. (1999) · The Journal of Nutrition · doi:10.1093/jn/129.3.758s · Cited by 1,158
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146
Estrogen receptor interaction with estrogen response elements
Klinge, C. M. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.14.2905 · Cited by 1,081
Production and Actions of Estrogens
Gruber, C. J., Tschugguel, W., Schneeberger, C., & Huber, J. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmra000471 · Cited by 1,062
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
Multiple Actions of Steroid Hormones—A Focus on Rapid, Nongenomic Effects
Falkenstein, E., Tillmann, H.-C., Christ, M., Feuring, M., & Wehling, M. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01468-6 · Cited by 991
“2) as shown for ER␣ (Brzozowski et al., 1997).”
Pike, A. C. W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.17.4608 · Cited by 986
Self-citationSetchell, K. D. R., Brown, N. M., Desai, P., Zimmer-Nechemias, L., Wolfe, B. E., Brashear, W. T., Kirschner, A. S., Cassidy, A., & Heubi, J. E. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.4.1362s · Cited by 973
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 968
Rosenfeld, M. G., Lunyak, V. V., & Glass, C. K. (2006) · Genes & Development · doi:10.1101/gad.1424806 · Cited by 952
“An additional helix required for ligand-dependent transcriptional activation (AF2) resides at the C terminus of the LBD and adopts different positions depending on the presence or absence of ligands (Bourguet et al. 1995; Renaud et al. 1995; Wagner et al. 1995; Brzozowski et al. 1997; Darimont et al. 1998; Moras and G…”
BackgroundAndrogen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943
“X-ray crystallographic studies demonstrate that AR, similar to PR, ER , and ER , lacks a helix 2 (95, 97, 100, 101).”
BackgroundMolecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
“The structure of the co-crystal complex of the ER agonist, diethylstilbestrol, with the ER LBD and a NR box-containing portion of the GRIP1 coactivator reveals that residues within helix 12 as well as within helices 3 and 5 are important for mediating interactions between ERs and coactivators (87, 88, 115).”
BackgroundStructure and specificity of nuclear receptor–coactivator interactions
Darimont, B. D., Wagner, R. L., Apriletti, J. W., Stallcup, M. R., Kushner, P. J., Baxter, J. D., Fletterick, R. J., & Yamamoto, K. R. (1998) · Genes & Development · doi:10.1101/gad.12.21.3343 · Cited by 924
“…from receptors for retinoids (RAR and RXR) (Bourguet et al. 1995; Renaud et al. 1995), thyroid hormone (TR) (Wagner et al. 1995), estrogen (ER) (Brzozowski et al. 1997), and progesterone (PR) (Williams and Sigler 1998) revealed a common overall fold for the domain, despite substantial sequence…”
BackgroundCyclical DNA methylation of a transcriptionally active promoter
Métivier, R., Gallais, R., Tiffoche, C., Le Péron, C., Jurkowska, R. Z., Carmouche, R. P., Ibberson, D., Barath, P., Demay, F., Reid, G., et al. (2008) · Nature · doi:10.1038/nature06544 · Cited by 900
De Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0006 · Cited by 898
High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery
Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., et al. (2001) · SLAS Discovery · doi:10.1177/108705710100600609 · Cited by 893
Estrogen receptor pathways to AP-1
Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., & Webb, P. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00108-4 · Cited by 870
“Crystal structures of the ER bound to either tarnoxifen, or raloxifene reveal that the SERMs prevent p160 binding by displacing helix 12 and rotating it 110 degrees so that it sits within the hydrophobic cleft, thereby occluding the p160 binding cleft [28,31].”
BackgroundSelf-citationEstrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860
Orphan Nuclear Receptors: From Gene to Function*
Giguère, V. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0378 · Cited by 855
The nuclear receptor ligand-binding domain: structure and function
Moras, D., & Gronemeyer, H. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80015-x · Cited by 843
The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand
Rochel, N., Wurtz, J. M., Mitschler, A., Klaholz, B., & Moras, D. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80413-x · Cited by 842
Bledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., Consler, T. G., Parks, D. J., Stewart, E. L., Willson, T. M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00817-6 · Cited by 818
Blair, R. M. (2000) · Toxicological Sciences · doi:10.1093/toxsci/54.1.138 · Cited by 806
“Crystallographic data of the ER complex with a number of chemicals, including E 2, DES, raloxifene and 4-hydroxytamoxifen, demonstrated that the critical spacing of hydrophobic and hydrogen bond interactions play a major role in determining binding affinity (Brzozowski et al., 1997; Shiau et al., 1998).”
BackgroundEstrogen Signaling: A Subtle Balance Between ER and ER
Matthews, J. (2003) · Molecular Interventions · doi:10.1124/mi.3.5.281 · Cited by 806
Self-citationBarkhem, T., Carlsson, B., Nilsson, Y., Enmark, E., Gustafsson, J.-Å., & Nilsson, S. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.105 · Cited by 779
“The ligand binding cavity of hERa is delimited by amino acid residues interspersed between amino acid residue 342 and amino acid residue 547 (Brzozowski et al., 1997).”
Self-citationThe Human Nuclear Xenobiotic Receptor PXR: Structural Determinants of Directed Promiscuity
Watkins, R. E., Wisely, G. B., Moore, L. B., Collins, J. L., Lambert, M. H., Williams, S. P., Willson, T. M., Kliewer, S. A., & Redinbo, M. R. (2001) · Science · doi:10.1126/science.1060762 · Cited by 760
Stauffer, S. R., Coletta, C. J., Tedesco, R., Nishiguchi, G., Carlson, K., Sun, J., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000170m · Cited by 760
Boron in Drug Discovery: Carboranes as Unique Pharmacophores in Biologically Active Compounds
Issa, F., Kassiou, M., & Rendina, L. M. (2011) · Chemical Reviews · doi:10.1021/cr2000866 · Cited by 759
Implications of protein flexibility for drug discovery
Teague, S. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1129 · Cited by 755
Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites
Hosie, A. M., Wilkins, M. E., da Silva, H. M. A., & Smart, T. G. (2006) · Nature · doi:10.1038/nature05324 · Cited by 752
Comparative Study of the Endocrine-Disrupting Activity of Bisphenol A and 19 Related Compounds
Kitamura, S. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi074 · Cited by 743
“…3-hydroxyl group of E2 interacts with Glu353 and Arg394 at the binding pocket of human estrogen receptor a via hydrogen bonding, and the 17bhydroxyl group interacts with His524, based on a crystallographic analysis of estrogen receptor a bound with E2 (Brzozowski et al., 1997; Shiau et al., 1998).”
BackgroundInfluentialBissantz, C., Folkers, G., & Rognan, D. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm001044l · Cited by 740
Crystallographic comparison of the estrogen and progesterone receptor’s ligand binding domains
Tanenbaum, D. M., Wang, Y., Williams, S. P., & Sigler, P. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5998 · Cited by 738
Reid, G., Hübner, M. R., Métivier, R., Brand, H., Denger, S., Manu, D., Beaudouin, J., Ellenberg, J., & Gannon, F. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00090-x · Cited by 732
The Mechanism of Action of Thyroid Hormones
Zhang, J., & Lazar, M. A. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.439 · Cited by 725
Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential
Paterni, I., Granchi, C., Katzenellenbogen, J. A., & Minutolo, F. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.012 · Cited by 721
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., & Schiff, R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.117 · Cited by 704
Glass, C. K., Rose, D. W., & Rosenfeld, M. G. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80066-x · Cited by 698
Basic Guide to the Mechanisms of Antiestrogen Action
Macgregor, J. I., & Jordan, V. C. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01358-9 · Cited by 694
“Clearly, the successful crystallization of ERa with raloxifene (Brzozowski et al., 1997) must act as a stimulus for the crystallization of ERb.”
InfluentialOverview of nomenclature of nuclear receptors
Germain, P., Staels, B., Dacquet, C., Spedding, M., & Laudet, V. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.2 · Cited by 688
“…of the ER (cid:1) LBD in complexes with the selective antiestrogen raloxifene and 4-hydroxytamoxifen and of the RAR (cid:1) LBD-BMS614 complex provided the first structural evidence for the molecular basis of antagonism (Brzozowski et al., 1997; Shiau et al., 1998; Bourguet et al., 2000b).”
BackgroundMartino, S., Cauley, J. A., Barrett-Connor, E., Powles, T. J., Mershon, J., Disch, D., Secrest, R. J., Cummings, S. R., & For the CORE Investigators (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh319 · Cited by 684
Thornton, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091553298 · Cited by 681
Cauley, J. A., Norton, L., Lippman, M. E., Eckert, S., Krueger, K. A., Purdie, D. W., Farrerons, J., Karasik, A., Mellstrom, D., Ng, K. W., et al. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1006478317173 · Cited by 678
“Consistent with the raloxifene results from MORE, tamoxifen had no effect on estrogen receptor-negative tumors [1], suggesting that these SERMs bind to the estrogen receptor in the breast to competitively inhibit estrogen-induced DNA transcription [12, 13].”
ResultActivating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy
Geller, D. S., Farhi, A., Pinkerton, N., Fradley, M., Moritz, M., Spitzer, A., Meinke, G., Tsai, F. T. F., Sigler, P. B., & Lifton, R. P. (2000) · Science · doi:10.1126/science.289.5476.119 · Cited by 675
Kallio, P. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.22.6573 · Cited by 666
“Three-dimensional studies of a number of ligand-binding domains of steroid receptors have documented conformational changes (Brzozowski et al., 1997 and references therein) which may possibly result in unmasking of the NLS.”
BackgroundAtomic structure of progesterone complexed with its receptor
Williams, S. P., & Sigler, P. B. (1998) · Nature · doi:10.1038/30775 · Cited by 659
Chen, H., Lin, R. J., Xie, W., Wilpitz, D., & Evans, R. M. (1999) · Cell · doi:10.1016/s0092-8674(00)80054-9 · Cited by 637
Setchell, K. D., Brown, N. M., Zimmer-Nechemias, L., Brashear, W. T., Wolfe, B. E., Kirschner, A. S., & Heubi, J. E. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.2.447 · Cited by 618
“However, genistein, the most extensively researched soy isoflavone, shows conformational binding to the estrogen receptor that classifies it as a natural selective estrogen receptor modulator rather than an estrogen (6, 7).”
BackgroundSteroid hormone receptors: an update
Beato, M. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.3.225 · Cited by 614
“The 3D-structure of the LBDs of hERα and hPR complexed with their natural ligands have been determined (Brzozowski et al., 1997; Tanenbaum et al., 1998).”
BackgroundDeterminants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation
McInerney, E. M., Rose, D. W., Flynn, S. E., Westin, S., Mullen, T.-M., Krones, A., Inostroza, J., Torchia, J., Nolte, R. T., Assa-Munt, N., et al. (1998) · Genes & Development · doi:10.1101/gad.12.21.3357 · Cited by 613
“Crystal structures of the carboxy-terminal ligand-binding domain of several receptors (Bourguet et al. 1995; Renaud et al. 1995; Wagner et al. 1995; Brzozowski et al. 1997; Nolte et al. 1998) reveal that the ligand is almost entirely buried within the conserved core of a helices 3, 7, and 10.”
BackgroundRecent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Ecdysone receptors and their biological actions
Riddiford, L. M., Cherbas, P., & Truman, J. W. (2000) · Vitamins & Hormones · doi:10.1016/s0083-6729(00)60016-x · Cited by 605
Co-activators and co-repressors in the integration of transcriptional responses
Torchia, J., Glass, C., & Rosenfeld, M. G. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80014-8 · Cited by 595
Estrogen Signaling through the Transmembrane G Protein–Coupled Receptor GPR30
Prossnitz, E. R., Arterburn, J. B., Smith, H. O., Oprea, T. I., Sklar, L. A., & Hathaway, H. J. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100518 · Cited by 590
“Its DNA sequence was determined in 1986 (31), and the first crystal structure of an ER ligand-binding domain was described in 1997 (32).”
BackgroundInternational Union of Pharmacology. LXIV. Estrogen Receptors
Dahlman-Wright, K., Cavailles, V., Fuqua, S. A., Jordan, V. C., Katzenellenbogen, J. A., Korach, K. S., Maggi, A., Muramatsu, M., Parker, M. G., & Gustafsson, J.-Å. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.8 · Cited by 583
“Several structures have been determined for ER and ER complexed with various ligands and cofactor peptides (Brzozowski et al., 1997).”
BackgroundSelf-citationHormone-Dependent Coactivator Binding to a Hydrophobic Cleft on Nuclear Receptors
Feng, W., Ribeiro, R. C. J., Wagner, R. L., Nguyen, H., Apriletti, J. W., Fletterick, R. J., Baxter, J. D., Kushner, P. J., & West, B. L. (1998) · Science · doi:10.1126/science.280.5370.1747 · Cited by 580
Connections and Regulation of the Human Estrogen Receptor
McDonnell, D. P., & Norris, J. D. (2002) · Science · doi:10.1126/science.1071884 · Cited by 579
Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors
Wang, Z., Benoit, G., Liu, J., Prasad, S., Aarnisalo, P., Liu, X., Xu, H., Walker, N. P. C., & Perlmann, T. (2003) · Nature · doi:10.1038/nature01645 · Cited by 578
“1b ), such as the 17β-oestradiol (E 2 )-bound oestrogen receptor α (ERα”
BackgroundGampe, R. T., Montana, V. G., Lambert, M. H., Miller, A. B., Bledsoe, R. K., Milburn, M. V., Kliewer, S. A., Willson, T. M., & Xu, H. E. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80448-7 · Cited by 574
The estrogen receptor: a model for molecular medicine.
Jensen, E. V., & Jordan, V. C. (2003) · PubMed · Cited by 573
Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model
Norman, A. W., Mizwicki, M. T., & Norman, D. P. G. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1283 · Cited by 569
Lonard, D. M., Nawaz, Z., Smith, C. L., & O'Malley, B. W. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80259-2 · Cited by 562
Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics
Huang, P., Chandra, V., & Rastinejad, F. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135917 · Cited by 533
“The antagonists often contain extended groups stemming from the center of their molecules, which directly impact H12 positioning and displace it into the LXXLL-binding site, accounting for their blocking of coactivator interactions and transcriptional activation (41, 42, 45, 47, 40).”
BackgroundChemistry and Structural Biology of Androgen Receptor
Gao, W., Bohl, C. E., & Dalton, J. T. (2005) · Chemical Reviews · doi:10.1021/cr020456u · Cited by 528
Resveratrol Acts as a Mixed Agonist/Antagonist for Estrogen Receptors α and β*
Bowers, J. L., Tyulmenkov, V. V., Jernigan, S. C., & Klinge, C. M. (2000) · Endocrinology · doi:10.1210/endo.141.10.7721 · Cited by 526
“Biochemical (29, 30, 44, 45) and crystal structure (46, 47) studies indicate ligand-specific differences in ERa conformation that impact interaction with coactivators.”
BackgroundShanle, E. K., & Xu, W. (2011) · Chemical Research in Toxicology · doi:10.1021/tx100231n · Cited by 522
The SRC family of nuclear receptor coactivators
Leo, C., & Chen, J. D. (2000) · Gene · doi:10.1016/s0378-1119(00)00024-x · Cited by 520
Hsu, K.-C., Chen, Y.-F., Lin, S.-R., & Yang, J.-M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-s1-s33 · Cited by 519
“These residues contribute the major vdW interactions for the ligand binding of estrogen receptor a [28,29].”
BackgroundManolagas, S. C. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.385 · Cited by 517
Molecular determinants of nuclear receptor-corepressor interaction
Perissi, V., Staszewski, L. M., McInerney, E. M., Kurokawa, R., Krones, A., Rose, D. W., Lambert, M. H., Milburn, M. V., Glass, C. K., & Rosenfeld, M. G. (1999) · Genes & Development · doi:10.1101/gad.13.24.3198 · Cited by 513
“…peroxisome proliferator-activated receptor g (PPARg) LBD structures, the AF2 helix is tightly packed against the body of the LBD domain and makes direct contacts with ligand (Renaud et al. 1995; Wagner et al. 1995; Brzozowski et al. 1997; Darimont et al. 1998; Nolte et al. 1998; Shiau et al. 1998).”
BackgroundCloning and Characterization of Human Estrogen Receptor β Isoforms
Moore, J. T., McKee, D. D., Slentz-Kesler, K., Moore, L. B., Jones, S. A., Horne, E. L., Su, J.-L., Kliewer, S. A., Lehmann, J. M., & Willson, T. M. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8738 · Cited by 511
Compston, J. E. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.419 · Cited by 511
Controlling nuclear receptors: the circular logic of cofactor cycles
Perissi, V., & Rosenfeld, M. G. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1680 · Cited by 510
Shevde, N. K., Bendixen, A. C., Dienger, K. M., & Pike, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130200197 · Cited by 502
Regulation of cytochrome P450 (CYP) genes by nuclear receptors
Honkakoski, P., & Negishi, M. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3470321 · Cited by 501
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Structure–function relationship of estrogen receptor α and β: Impact on human health
Ascenzi, P., Bocedi, A., & Marino, M. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.07.001 · Cited by 499
The nuclear receptor superfamily: A structural perspective
Weikum, E. R., Liu, X., & Ortlund, E. A. (2018) · Protein Science · doi:10.1002/pro.3496 · Cited by 495
“4(A) and (B)].(83,84) A striking example of the importance of these hydrogen bond networks in the LBP is seen in FXR and LXR ligands; although similar, these ligands are bound in completely opposite orientations due to the available hydrogen bonding network within the LBP [Fig.”
Background
Metadata
- Authors
- Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M.
- Affiliations
- University of York (GB)
- Karo Pharma (Sweden) (SE)
- University of Chicago (US)
- Corresponding author
- Hubbard, Roderick E.
- ORCID
- Venue
- Nature
- Published
- 1997-10
- Volume
- 389
- Issue
- 6652
- Pages
- 753-758
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2101738855
- Cited by
- 3,355
- References
- 29
- Citations by year
- 2026: 49 · 2025: 55 · 2024: 55 · 2023: 61 · 2022: 62 · 2021: 91 · 2020: 55 · 2019: 75 · 2018: 73 · 2017: 65 · 2016: 72 · 2015: 74 · 2014: 94 · 2013: 105 · 2012: 104
- FWCI
- 94.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- oestrogen receptor, ligand-binding domain, estradiol, raloxifene, selective estrogen receptor modulators, crystal structure, transcriptional regulation
- MeSH terms
- Binding Sites, Estradiol, Estrogen Antagonists, Humans, Models, Molecular, Piperidines, Protein Conformation, Receptors, Estrogen, Crystallography, X-Ray, Raloxifene Hydrochloride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.